Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Iparomlimab/Tuvonralimab + CAPEOX +/- Propranolol for Locally Advanced pMMR Colon Cancer
NCT07549906Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2026
- Primary completion
- Jul 2026
- Modality
- Small Molecules, Monoclonal Antibodies, Fc-Fusion Proteins
01
Overview
A Phase 2 trial of iparomlimab + tuvonralimab, propranolol in colon cancer, sponsored by Sun Yat-sen University. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimabpropranolol
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT07549906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07549906.